Navigation Links
Pharmasset to Present at Two Upcoming Investor Conferences
Date:3/3/2009

Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing four product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. An IND for PSI-7851, a second generation nucleotide HCV inhibitor was filed in January 2009. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation,, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk th
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Pharmassets Underwriters Release Shares from Lock-Up
2. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
3. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
4. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
5. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
6. Pharmasset to Webcast an Investor Event from the AASLD Meeting
7. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
8. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... (PRWEB) July 14, 2014 Sometimes, thinking ... company Passionate Playground announces its first product release, Joyboxx™ ... product storage system. , Inventor and CEO, ... consumers to have a storage solution for their ‘toys’ ... multibillion dollar adult retail industry. , Semer met 30-year ...
(Date:7/14/2014)... 2014 AttorneyOne.com, a recognized authority on ... information from the FDA on Hospira Lactated Ringer’s ... on July 11, that one lot of Lactated Ringers ... by Hospira Inc., is recalled due to mold contamination. ... extracellular losses of fluid and electrolytes, with or without ...
(Date:7/14/2014)... According to the Boost Your Bust book review recently ... want to learn how to increase the size of their breasts ... chapters including:, , Chapter 1 – What Are ... 2 – How Natural Breast Enlargement Works , Chapter ... Chapter 4 – The Groundwork , Chapter ...
(Date:7/14/2014)... Reha Technology today announced the ... and full-featured upper extremity robotic trainer that offers ... games and challenges in a lightweight and economic ... Armotion combines a variety of complex ... the therapy effect for patients with severe and ...
(Date:7/14/2014)... TherapySites, the leading ... professionals, announced today its affiliation with the ... This new relationship allows TherapySites to continue ... members, adding exclusive benefits and promotional offers. , ... dedicated to providing online marketing solutions specifically for ...
Breaking Medicine News(10 mins):Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 2Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 3Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Reha Technology Launches the Armotion™, a Device for the Rehabilitation of the Upper Extremity 2Health News:TherapySites Partners With the Licensed Professional Counselors Association of North Carolina to Make Online Marketing Available to All Therapists 2
... University School of Medicine (BUSM) have quantified the probability ... of the Huntington,s Disease (HD) gene having a child ... very rare event, the probability has never been estimated ... appear on-line in the American Journal of Medical ...
... For matters of health, where you get your information matters ... living is just one click away. , , SCOTTS ... Institute of Alternative Health Care announces today the first nationally ... www.althealthconnect.com ). , , The Alternative Health Connection was ...
... and SCA Personal Care North America , Through its TENA(R) ... National Online, Offline and Grassroots Education Initiatives , , ... the United States are affected by urinary incontinence(1), research shows they,re ... women to talk about their health(2), and when it comes to ...
... June 2009 - Researchers have been seeking a ... associated with schizophrenia by enhancing N-methyl-D-aspartate (NMDA) glutamate ... contribute to the underlying neurobiology of this disorder. ... NMDA receptors administered large amounts of substances, like ...
... Pharmaceutical Inc. (Nasdaq: BMRN ) today announced ... (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of ... Phase 2 clinical study in late June or early ... clinical trial sites. The U.S. Food and Drug ...
... 9 Bruce Matter has joined healthcare IT software ... company growth and client satisfaction. Peminic, with offices in ... management solutions to over 400 acute care and other ... and legal matters. , , Teaming with hospitals, ...
Cached Medicine News:Health News:Researchers estimate risk of transmission of Huntington's disease to offspring among male carriers 2Health News:NIAHC Premiers It's Natural Health Care and Balanced Living Website 2Health News:Bringing Incontinence Out of the Bathroom and Into the Spotlight 2Health News:Bringing Incontinence Out of the Bathroom and Into the Spotlight 3Health News:Bringing Incontinence Out of the Bathroom and Into the Spotlight 4Health News:Bringing Incontinence Out of the Bathroom and Into the Spotlight 5Health News:Animal model for schizophrenia identifies a novel approach for treating cognitive impairments 2Health News:Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study 2Health News:Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study 3Health News:Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study 4Health News:Industry Recognized and Trusted Leader, Bruce Matter, Joins Healthcare IT Company, Peminic, Inc. as Company Growth in the Areas of Patient Safety, Risk Management, and Patient Satisfaction Accelerates 2
(Date:7/10/2014)... 10, 2014 Yesterday, former Congressman ... device manufacturing facility. Rep. Kennedy and Dick ... facilitate cutting-edge research in neurological disease and treatment. ... health advocate, Garen Staglin , created One ... fundamental changes that will radically accelerate the development ...
(Date:7/10/2014)...   LabStyle Innovations Corp . (OTCQB:DRIO), developer of ... appointment of Professor Richard B. Stone ... Directors. Prof. Stone brings over forty-five ... as an entrepreneur, venture capitalist public, company officer ... He currently serves on the board of directors ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Control, Inc. (Nasdaq: SPEC ), a leading designer ... that it will release its fourth quarter and fiscal year ... of the market. Following the release, Spectrum Control will host ... the Company,s operating results for the quarter and fiscal year ...
... Animal Health today announced an agreement to acquire ... a privately held, Kansas City-based leader in the ... companion and food production animals.   ... using antigen-antibody reaction to detect viruses or bacteria ...
Cached Medicine Technology:Pfizer Animal Health to Acquire Synbiotics Corporation, Entering Diagnostics Sector 2Pfizer Animal Health to Acquire Synbiotics Corporation, Entering Diagnostics Sector 3Pfizer Animal Health to Acquire Synbiotics Corporation, Entering Diagnostics Sector 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: